312 related articles for article (PubMed ID: 33860090)
1. Probiotics for Parkinson's disease: Current evidence and future directions.
Tan AH; Hor JW; Chong CW; Lim SY
JGH Open; 2021 Apr; 5(4):414-419. PubMed ID: 33860090
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation.
Metta V; Leta V; Mrudula KR; Prashanth LK; Goyal V; Borgohain R; Chung-Faye G; Chaudhuri KR
J Neurol; 2022 Mar; 269(3):1154-1163. PubMed ID: 33881598
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiome and Parkinson's disease: Perspective on pathogenesis and treatment.
Salim S; Ahmad F; Banu A; Mohammad F
J Adv Res; 2023 Aug; 50():83-105. PubMed ID: 36332796
[TBL] [Abstract][Full Text] [Related]
4. Microbiota- Brain-Gut-Axis Relevance to Parkinson's Disease: Potential Therapeutic Effects of Probiotics.
Raj K; Singh S; Chib S; Mallan S
Curr Pharm Des; 2022; 28(37):3049-3067. PubMed ID: 36200207
[TBL] [Abstract][Full Text] [Related]
5. Role of the Gut-Brain Axis, Gut Microbial Composition, Diet, and Probiotic Intervention in Parkinson's Disease.
Thangaleela S; Sivamaruthi BS; Kesika P; Bharathi M; Chaiyasut C
Microorganisms; 2022 Jul; 10(8):. PubMed ID: 36013962
[TBL] [Abstract][Full Text] [Related]
6. Probiotics Alleviate the Progressive Deterioration of Motor Functions in a Mouse Model of Parkinson's Disease.
Hsieh TH; Kuo CW; Hsieh KH; Shieh MJ; Peng CW; Chen YC; Chang YL; Huang YZ; Chen CC; Chang PK; Chen KY; Chen HY
Brain Sci; 2020 Apr; 10(4):. PubMed ID: 32244769
[TBL] [Abstract][Full Text] [Related]
7. Neurogenic and anti-inflammatory effects of probiotics in Parkinson's disease: A systematic review of preclinical and clinical evidence.
Leta V; Ray Chaudhuri K; Milner O; Chung-Faye G; Metta V; Pariante CM; Borsini A
Brain Behav Immun; 2021 Nov; 98():59-73. PubMed ID: 34364965
[TBL] [Abstract][Full Text] [Related]
8. Effects of a probiotic suspension Symprove™ on a rat early-stage Parkinson's disease model.
Sancandi M; De Caro C; Cypaite N; Marascio N; Avagliano C; De Marco C; Russo E; Constanti A; Mercer A
Front Aging Neurosci; 2022; 14():986127. PubMed ID: 36742204
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of randomized controlled trials of the effects of probiotics in Parkinson's disease.
Chu C; Yu L; Li Y; Guo H; Zhai Q; Chen W; Tian F
Food Funct; 2023 Apr; 14(8):3406-3422. PubMed ID: 36974511
[No Abstract] [Full Text] [Related]
10. Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease.
Dodiya HB; Forsyth CB; Voigt RM; Engen PA; Patel J; Shaikh M; Green SJ; Naqib A; Roy A; Kordower JH; Pahan K; Shannon KM; Keshavarzian A
Neurobiol Dis; 2020 Feb; 135():104352. PubMed ID: 30579705
[TBL] [Abstract][Full Text] [Related]
11. Microbiota-mediated effects of Parkinson's disease medications on Parkinsonian non-motor symptoms in male transgenic mice.
Radisavljevic N; Metcalfe-Roach A; Cirstea M; Tabusi MM; Bozorgmehr T; Bar-Yoseph H; Finlay BB
mSphere; 2024 Jan; 9(1):e0037923. PubMed ID: 38078745
[TBL] [Abstract][Full Text] [Related]
12. Probiotics and the Treatment of Parkinson's Disease: An Update.
Mirzaei H; Sedighi S; Kouchaki E; Barati E; Dadgostar E; Aschner M; Tamtaji OR
Cell Mol Neurobiol; 2022 Nov; 42(8):2449-2457. PubMed ID: 34283340
[TBL] [Abstract][Full Text] [Related]
13. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis.
Zhao Z; Ning J; Bao XQ; Shang M; Ma J; Li G; Zhang D
Microbiome; 2021 Nov; 9(1):226. PubMed ID: 34784980
[TBL] [Abstract][Full Text] [Related]
14. Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson's Disease.
Caputi V; Giron MC
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29882798
[TBL] [Abstract][Full Text] [Related]
15. Effect of
Yang X; He X; Xu S; Zhang Y; Mo C; Lai Y; Song Y; Yan Z; Ai P; Qian Y; Xiao Q
Food Funct; 2023 Jul; 14(15):6828-6839. PubMed ID: 37470081
[TBL] [Abstract][Full Text] [Related]
16. Gut Microbiota: A Novel Therapeutic Target for Parkinson's Disease.
Zhu M; Liu X; Ye Y; Yan X; Cheng Y; Zhao L; Chen F; Ling Z
Front Immunol; 2022; 13():937555. PubMed ID: 35812394
[TBL] [Abstract][Full Text] [Related]
17. Buty and the beast: the complex role of butyrate in Parkinson's disease.
Elford JD; Becht N; Garssen J; Kraneveld AD; Perez-Pardo P
Front Pharmacol; 2024; 15():1388401. PubMed ID: 38694925
[TBL] [Abstract][Full Text] [Related]
18. Dysbiosis of gut microbiota and microbial metabolites in Parkinson's Disease.
Sun MF; Shen YQ
Ageing Res Rev; 2018 Aug; 45():53-61. PubMed ID: 29705121
[TBL] [Abstract][Full Text] [Related]
19. Probiotic Clostridium butyricum ameliorated motor deficits in a mouse model of Parkinson's disease via gut microbiota-GLP-1 pathway.
Sun J; Li H; Jin Y; Yu J; Mao S; Su KP; Ling Z; Liu J
Brain Behav Immun; 2021 Jan; 91():703-715. PubMed ID: 33148438
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of probiotics in gut microbial homeostasis and Rheumatoid arthritis.
Balasundaram D; Veerasamy V; Sylvia Singarayar M; Neethirajan V; Ananth Devanesan A; Thilagar S
Int Immunopharmacol; 2024 Jun; 137():112501. PubMed ID: 38885604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
